Current:Home > NewsElon Musk's X worth 71.5% less than it was when he bought the platform in 2022, Fidelity says -Aspire Money Growth
Elon Musk's X worth 71.5% less than it was when he bought the platform in 2022, Fidelity says
View
Date:2025-04-15 20:56:34
X, the social media platform formerly known as Twitter, is now worth an estimated 71.5% less than it was when Elon Musk purchased the platform in Oct. 2022, according to a Fidelity securities filing dated Dec. 30, 2023.
The asset management firm, which owns an equity stake in the company under X Holdings Corp., previously slashed X's valuation to a third of Musk's $44 billion purchase price in May of last year.
The new valuation from Fidelity's Blue Chip Growth Fund, which reported data through Nov. 30, 2023, estimates that its shares of X are worth $5.3 million — down from an estimated $6.3 million in October and far from the $19.66 million valuation of its stake just prior to Musk's takeover.
The many controversies that have plagued the platform since the Tesla CEO's purchase scared off advertisers and resulted in more than half of them halting spending on X less than a month after Musk's acquisition was finalized.
In November, major advertisers including Disney, Apple, and Coca Cola pulled paid advertising off the platform to distance themselves from Musk after his endorsement of an antisemitic post.
Musk had praised a post that said Jews "have been pushing the exact kind of dialectical hatred against whites that they claim to want people to stop using against them."
He has since apologized. "I am quite sorry," he said at The New York Times' DealBook Summit in November last year, adding, "I should, in retrospect, not have replied to that particular post."
Musk said that the ad boycott could "kill the company," but he defiantly added, "I hope they stop. Don't advertise," he said at the summit.
"If somebody is going to try to blackmail me with advertising, blackmail me with money, go f**k yourself. Go f**k yourself. Is that clear? I hope it is."
- In:
- Elon Musk
- X
- Antisemitism
C Mandler is a social media producer and trending topics writer for CBS News, focusing on American politics and LGBTQ+ issues.
veryGood! (961)
Related
- Federal appeals court upholds $14.25 million fine against Exxon for pollution in Texas
- 2016: California’s ‘Staggering’ Leak Could Spew Methane for Months
- How Life Will Change for Prince George, Princess Charlotte and Prince Louis After the Coronation
- Virginia graduation shooting that killed teen, stepdad fueled by ongoing dispute, police say
- 2025 'Doomsday Clock': This is how close we are to self
- How Kate Middleton Honored Queen Elizabeth II and Princess Diana at Coronation
- Chris Christie announces 2024 presidential campaign by going after Trump
- What's it take to go from mechanic to physician at 51? Patience, an Ohio doctor says
- Sonya Massey's father decries possible release of former deputy charged with her death
- Botched Smart Meter Roll Outs Provoking Consumer Backlash
Ranking
- US wholesale inflation accelerated in November in sign that some price pressures remain elevated
- Is California’s Drought Returning? Snowpack Nears 2015’s Historic Lows
- J&J tried to block lawsuits from 40,000 cancer patients. A court wants answers
- Everything to Know About King Charles III's Coronation
- Former Danish minister for Greenland discusses Trump's push to acquire island
- Today’s Climate: June 9, 2010
- Why Pregnant Serena Williams Kept Baby No. 2 a Secret From Daughter Olympia Until Met Gala Reveal
- What's it take to go from mechanic to physician at 51? Patience, an Ohio doctor says
Recommendation
Pressure on a veteran and senator shows what’s next for those who oppose Trump
North Dakota Republican Gov. Doug Burgum launches 2024 run for president
Everything to Know About King Charles III's Coronation
Climate Change Is Happening Faster Than Expected, and It’s More Extreme
Mets have visions of grandeur, and a dynasty, with Juan Soto as major catalyst
Today’s Climate: June 3, 2010
Troubled by Trump’s Climate Denial, Scientists Aim to Set the Record Straight
FDA seems poised to approve a new drug for ALS, but does it work?